{
    "root": "10b6e3b3-2a43-4b70-933a-eda085d74239",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ropinirole",
    "value": "20250327",
    "ingredients": [
        {
            "name": "ROPINIROLE HYDROCHLORIDE",
            "code": "D7ZD41RZI9",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8889"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": {
        "text": "ropinirole tablets non-ergoline dopamine agonist indicated treatment parkinson \u2019 disease ( pd ) moderate-to-severe primary restless legs syndrome ( rls ) . ( 1.1 , 1.2 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "restless legs syndrome (DOID:0050425)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050425"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe primary restless",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_468726"
            }
        ]
    },
    "contraindications": {
        "text": "ropinirole tablets taken without food . ( 2.1 ) retitration ropinirole may warranted therapy interrupted . ( 2.1 ) parkinson \u2019 disease : recommended starting dose 0.25 mg taken three times daily ; titrate maximum daily dose 24 mg. ( 2.2 ) renal impairment : maximum recommended dose 18 mg/day patients end-stage renal disease hemodialysis . ( 2.2 ) restless legs syndrome : recommended starting dose 0.25 mg daily , 1 3 hours bedtime , titrate maximum recommended dose 4 mg daily . ( 2.3 ) renal impairment : maximum recommended dose 3 mg/day patients end-stage renal disease hemodialysis . ( 2.3 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "restless legs syndrome (DOID:0050425)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050425"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ropinirole hydrochloride , usp 1 mg : pale green coloured , modified oval shaped , biconvex , film-coated tablet debossed \u201c 107 \u201d one side \u201c rh \u201d side . ndc : 71335-9656-1 : 30 tablets bottle ndc : 71335-9656-2 : 28 tablets bottle ndc : 71335-9656-3 : 90 tablets bottle ndc : 71335-9656-4 : 60 tablets bottle ndc : 71335-9656-5 : 100 tablets bottle store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . protect light moisture . close container tightly . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "ropinirole contraindicated patients known hypersensitivity/allergic reaction ( including urticaria , angioedema , rash , pruritus ) ropinirole excipients .",
    "indications_original": "Ropinirole tablets are a non-ergoline dopamine agonist indicated for the treatment of Parkinson\u2019s disease (PD) and moderate-to-severe primary Restless Legs Syndrome (RLS). (1.1, 1.2)",
    "contraindications_original": "Ropinirole tablets can be taken with or without food. (2.1) Retitration of ropinirole may be warranted if therapy is interrupted. (2.1) Parkinson\u2019s Disease : The recommended starting dose is 0.25 mg taken three times daily; titrate to a maximum daily dose of 24 mg. (2.2) Renal Impairment: The maximum recommended dose is 18 mg/day in patients with end-stage renal disease on hemodialysis. (2.2) Restless Legs Syndrome: The recommended starting dose is 0.25 mg once daily, 1 to 3 hours before bedtime, titrate to a maximum recommended dose of 4 mg daily. (2.3) Renal Impairment: The maximum recommended dose is 3 mg/day in patients with end-stage renal disease on hemodialysis. (2.3)",
    "warningsAndPrecautions_original": "Ropinirole hydrochloride, USP 1 mg: pale green coloured, modified oval shaped, biconvex, film-coated tablet debossed with \u201c107\u201d on one side and \u201cRH\u201d on the other side.\n                  NDC: 71335-9656-1: 30 Tablets in a BOTTLE\n                  NDC: 71335-9656-2: 28 Tablets in a BOTTLE\n                  NDC: 71335-9656-3: 90 Tablets in a BOTTLE\n                  NDC: 71335-9656-4: 60 Tablets in a BOTTLE\n                  NDC: 71335-9656-5: 100 Tablets in a BOTTLE\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from light and moisture. Close container tightly after each use.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Ropinirole is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients.",
    "drug": [
        {
            "name": "Ropinirole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8888"
        }
    ]
}